Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503)

final results of an open-label, phase 1/2 study

Torben Plesner*, Hendrik Tobias Arkenau, Francesca Gay, Monique C. Minnema, Mario Boccadoro, Philippe Moreau, Jamie Cavenagh, Aurore Perrot, Jacob P. Laubach, Jakub Krejcik, Tahamtan Ahmadi, Carla de Boer, Diana Chen, Christopher Chiu, Jordan M. Schecter, Paul G. Richardson

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftLetterForskningpeer review

OriginalsprogEngelsk
TidsskriftBritish Journal of Haematology
Vol/bind186
Udgave nummer3
Sider (fra-til)e35-e39
ISSN0007-1048
DOI
StatusUdgivet - aug. 2019

Citer dette

Plesner, Torben ; Arkenau, Hendrik Tobias ; Gay, Francesca ; Minnema, Monique C. ; Boccadoro, Mario ; Moreau, Philippe ; Cavenagh, Jamie ; Perrot, Aurore ; Laubach, Jacob P. ; Krejcik, Jakub ; Ahmadi, Tahamtan ; de Boer, Carla ; Chen, Diana ; Chiu, Christopher ; Schecter, Jordan M. ; Richardson, Paul G. / Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503) : final results of an open-label, phase 1/2 study. I: British Journal of Haematology. 2019 ; Bind 186, Nr. 3. s. e35-e39.
@article{455627ccb62f464784a909ee1d968591,
title = "Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study",
keywords = "daratumumab, monoclonal antibody, multiple myeloma, plasma cell disorders, relapsed/refractory multiple myeloma",
author = "Torben Plesner and Arkenau, {Hendrik Tobias} and Francesca Gay and Minnema, {Monique C.} and Mario Boccadoro and Philippe Moreau and Jamie Cavenagh and Aurore Perrot and Laubach, {Jacob P.} and Jakub Krejcik and Tahamtan Ahmadi and {de Boer}, Carla and Diana Chen and Christopher Chiu and Schecter, {Jordan M.} and Richardson, {Paul G.}",
year = "2019",
month = "8",
doi = "10.1111/bjh.15879",
language = "English",
volume = "186",
pages = "e35--e39",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

Plesner, T, Arkenau, HT, Gay, F, Minnema, MC, Boccadoro, M, Moreau, P, Cavenagh, J, Perrot, A, Laubach, JP, Krejcik, J, Ahmadi, T, de Boer, C, Chen, D, Chiu, C, Schecter, JM & Richardson, PG 2019, 'Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study', British Journal of Haematology, bind 186, nr. 3, s. e35-e39. https://doi.org/10.1111/bjh.15879

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503) : final results of an open-label, phase 1/2 study. / Plesner, Torben; Arkenau, Hendrik Tobias; Gay, Francesca; Minnema, Monique C.; Boccadoro, Mario; Moreau, Philippe; Cavenagh, Jamie; Perrot, Aurore; Laubach, Jacob P.; Krejcik, Jakub; Ahmadi, Tahamtan; de Boer, Carla; Chen, Diana; Chiu, Christopher; Schecter, Jordan M.; Richardson, Paul G.

I: British Journal of Haematology, Bind 186, Nr. 3, 08.2019, s. e35-e39.

Publikation: Bidrag til tidsskriftLetterForskningpeer review

TY - JOUR

T1 - Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503)

T2 - final results of an open-label, phase 1/2 study

AU - Plesner, Torben

AU - Arkenau, Hendrik Tobias

AU - Gay, Francesca

AU - Minnema, Monique C.

AU - Boccadoro, Mario

AU - Moreau, Philippe

AU - Cavenagh, Jamie

AU - Perrot, Aurore

AU - Laubach, Jacob P.

AU - Krejcik, Jakub

AU - Ahmadi, Tahamtan

AU - de Boer, Carla

AU - Chen, Diana

AU - Chiu, Christopher

AU - Schecter, Jordan M.

AU - Richardson, Paul G.

PY - 2019/8

Y1 - 2019/8

KW - daratumumab

KW - monoclonal antibody

KW - multiple myeloma

KW - plasma cell disorders

KW - relapsed/refractory multiple myeloma

U2 - 10.1111/bjh.15879

DO - 10.1111/bjh.15879

M3 - Letter

VL - 186

SP - e35-e39

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -